Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma

Abstract

BackgroundIntratumoral heterogeneity hampers the success of marker-based anticancer treatment because the targeted therapy may eliminate a specific subpopulation of tumor cells while leaving others unharmed. Accordingly, a rational strategy minimizing survival of the drug-resistant subpopulation is essential to achieve long-term therapeutic efficacy.ResultsUsing single-cell RNA sequencing (RNA-seq), we examine the intratumoral heterogeneity of a pair of primary renal cell carcinoma and its lung metastasis. Activation of drug target pathways demonstrates considerable variability between the primary and metastatic sites, as well as among individual cancer cells within each site. Based on the prediction of multiple drug target pathway activation, we derive a combinatorial regimen co-targeting two mutually exclusive pathways for the metastatic cancer cells. This combinatorial strategy shows significant increase in the treatment efficacy over monotherapy in the experimental validation using patient-derived xenograft platforms in vitro and in vivo.ConclusionsOur findings demonstrate the investigational application of single-cell RNA-seq in the design of an anticancer regimen. The approach may overcome intratumoral heterogeneity which hampers the success of precision medicine.Electronic supplementary materialThe online version of this article (doi:10.1186/s13059-016-0945-9) contains supplementary material, which is available to authorized users.

Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer

“…Among emerging technologies, scRNA-seq has facilitated the identification of developmental hierarchies, drug resistance programs, and patterns of immune infiltration relevant to tumor biology, diagnosis, and therapy (Kim et al, 2016; Li et al, 2017; Patel et al, 2014; Tirosh et al, 2016a; Tirosh et al, 2016b; Venteicher et al, 2017). Here, we applied the approach to characterize primary HNSCC tumors and matched LN metastases.…”

The promise of single-cell RNA sequencing for kidney disease investigation

“…The other application was reported by Kim et al also using Fluidigm C1 system. 51 scRNA-seq profiling of 161 kidney cells from renal cell carcinoma patients enables them to develop a combinatorial regimen that targets two pathways in the cancer cells. Based on scRNAseq data, they proposed single-cell analysis-driven therapeutic strategy, which can be easily applied to other fields.…”

Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis

“…This new methodology has been applied in many fields, including in cancer where the analysis of the heterogeneity of tumor cells suggested potentially more effective therapeutic targeting approaches specifically directed at pathogenic tumor lineages (13,14). Recently, scRNA-seq has been applied to renal carcinoma cells to differentiate between primary and metastatic tumor cells (15). Similarly, we applied this technology to LN tissue in order to characterize gene expression at the single cell level and resolve differential responses by cell type, in order to understand how activated and quiescent, resident (i.e., tissue-constituting), and/or infiltrating cellular subpopulations contribute to disease initiation, maintenance, and progression.…”